[EN] TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES À TITRE D'INHIBITEURS DE LA MPGES-1
申请人:GLENMARK PHARMACEUTICALS SA
公开号:WO2013153535A1
公开(公告)日:2013-10-17
The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as m PGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
本公开涉及式(I)的化合物及其药学上可接受的盐,作为m PGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1(m PGES-1)酶的抑制剂,因此在治疗来自多种疾病或状况的疼痛和/或炎症方面非常有用,如哮喘、骨关节炎、风湿性关节炎、急性或慢性疼痛和神经退行性疾病。